Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-04-25

AUTHORS

Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger

ABSTRACT

BACKGROUND: Surgical resection of liver metastases arising from colorectal cancer is considered the only curative treatment option. However, many patients subsequently experience disease recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of recurrence following potentially curative liver resection. Special emphasis was directed to the importance of response. METHODS: 50 patients with resectable liver metastases received neoadjuvant XELOX or FOLFOX4 for six cycles (3 months). Complete resection of liver metastases was intended thereafter. Assessments included response rate, postoperative morbidity and recurrence-free survival. RESULTS: An objective response was observed in 72% of all patients, including two complete responses. Chemotherapy was well tolerated and the majority of adverse events were mild to moderate (grade 1/2). Potentially curative R0 resection was performed in all patients and postoperative complications were observed in only 12%. The median recurrence-free survival was significantly influenced by tumor response with 24.7 months (95% CI: 4.50 to 44.97) in responding patients, 8.2 months (95% CI: 3.09 to 13.31) in patients with stable disease and 3.0 months (95% CI: 0 to 8.91) in patients with progressive disease. CONCLUSION: These data suggest that neoadjuvant Oxaliplatin based chemotherapy provides high response rates without increased risk of perioperative morbidity. Response to chemotherapy can lead to long-term recurrence-free survival. Neoadjuvant chemotherapy may identify best candidates for a potentially curative treatment approach. More... »

PAGES

120-120

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-8-120

DOI

http://dx.doi.org/10.1186/1471-2407-8-120

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037616467

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18439246


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxaliplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxaloacetates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Medical University Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Medicine, Medical University Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gruenberger", 
        "givenName": "Birgit", 
        "id": "sg:person.01356576431.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356576431.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Medical University Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Medicine, Medical University Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scheithauer", 
        "givenName": "Werner", 
        "id": "sg:person.0713515512.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713515512.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, LKH Amstetten, Austria", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine, LKH Amstetten, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Punzengruber", 
        "givenName": "Robert", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Medical University Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Medicine, Medical University Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zielinski", 
        "givenName": "Christoph", 
        "id": "sg:person.01201545125.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201545125.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamandl", 
        "givenName": "Dietmar", 
        "id": "sg:person.01307322440.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307322440.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gruenberger", 
        "givenName": "Thomas", 
        "id": "sg:person.01156246422.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156246422.84"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10353-006-0229-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029392862", 
          "https://doi.org/10.1007/s10353-006-0229-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-59745-215-1_10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021439147", 
          "https://doi.org/10.1007/978-1-59745-215-1_10"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-04-25", 
    "datePublishedReg": "2008-04-25", 
    "description": "BACKGROUND: Surgical resection of liver metastases arising from colorectal cancer is considered the only curative treatment option. However, many patients subsequently experience disease recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of recurrence following potentially curative liver resection. Special emphasis was directed to the importance of response.\nMETHODS: 50 patients with resectable liver metastases received neoadjuvant XELOX or FOLFOX4 for six cycles (3 months). Complete resection of liver metastases was intended thereafter. Assessments included response rate, postoperative morbidity and recurrence-free survival.\nRESULTS: An objective response was observed in 72% of all patients, including two complete responses. Chemotherapy was well tolerated and the majority of adverse events were mild to moderate (grade 1/2). Potentially curative R0 resection was performed in all patients and postoperative complications were observed in only 12%. The median recurrence-free survival was significantly influenced by tumor response with 24.7 months (95% CI: 4.50 to 44.97) in responding patients, 8.2 months (95% CI: 3.09 to 13.31) in patients with stable disease and 3.0 months (95% CI: 0 to 8.91) in patients with progressive disease.\nCONCLUSION: These data suggest that neoadjuvant Oxaliplatin based chemotherapy provides high response rates without increased risk of perioperative morbidity. Response to chemotherapy can lead to long-term recurrence-free survival. Neoadjuvant chemotherapy may identify best candidates for a potentially curative treatment approach.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2407-8-120", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "recurrence-free survival", 
      "liver metastases", 
      "neoadjuvant chemotherapy", 
      "long-term recurrence-free survival", 
      "response rate", 
      "colorectal cancer liver metastases", 
      "median recurrence-free survival", 
      "curative liver resection", 
      "resectable liver metastases", 
      "curative R0 resection", 
      "curative treatment option", 
      "cancer liver metastases", 
      "curative treatment approach", 
      "risk of recurrence", 
      "high response rate", 
      "neoadjuvant oxaliplatin", 
      "R0 resection", 
      "stable disease", 
      "postoperative morbidity", 
      "objective response", 
      "postoperative complications", 
      "progressive disease", 
      "perioperative morbidity", 
      "surgical resection", 
      "liver resection", 
      "complete response", 
      "adverse events", 
      "disease recurrence", 
      "complete resection", 
      "colorectal cancer", 
      "treatment options", 
      "tumor response", 
      "chemotherapy", 
      "patients", 
      "treatment approaches", 
      "resection", 
      "importance of response", 
      "metastasis", 
      "months", 
      "morbidity", 
      "recurrence", 
      "survival", 
      "disease", 
      "risk", 
      "response", 
      "XELOX", 
      "FOLFOX4", 
      "complications", 
      "oxaliplatin", 
      "cancer", 
      "rate", 
      "options", 
      "majority", 
      "special emphasis", 
      "assessment", 
      "good candidate", 
      "events", 
      "importance", 
      "candidates", 
      "data", 
      "cycle", 
      "emphasis", 
      "approach", 
      "neoadjuvant XELOX", 
      "curable colorectal cancer liver metastases"
    ], 
    "name": "Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases", 
    "pagination": "120-120", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037616467"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-8-120"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18439246"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-8-120", 
      "https://app.dimensions.ai/details/publication/pub.1037616467"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_477.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2407-8-120"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-120'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-120'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-120'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-120'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      22 PREDICATES      114 URIs      104 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-8-120 schema:about N04f3a314a9fb4f4590a2b12d481a8d79
2 N0da2a3a354ab40949bc0af6293b55a8a
3 N41829b8d5d144b77adcbe6a64f5c0c19
4 N5a5da3b12fc1418cbdc5a37a4695840e
5 N5b46e9fa5d484390b1508f67a5d7acc9
6 N5d9d2aa9fd1a4f2d9258317c5f973685
7 N6cdcfbaa5c444c4facbadf83326cc8ef
8 N71ef2433067e4a639af369b35b65e09d
9 N8ebd36a95c2149f2aba2f5f3e92e7ae0
10 N940addeca8c0418bb7a9e4262a1e7be7
11 N99dce638e5f146e68b9c5ff1fec0a334
12 N9e2e7b4c40df4f31915d5663cf06d6f7
13 Nbd697bf2b8914054ac8b4834bfbd4428
14 Nc23bc3b819fe4792b287f671ab515ac4
15 Ne14e209fb07948418aa9d50de0a60544
16 Ne2cde5a7e0644a50a42094d31f1dfe8c
17 Nef969d1ef13549f8b98cd7b44d2769aa
18 Nf8a71bc62ff5416880480e73fa66b16a
19 Nf95f96f93bc2409e93ebfb9df9c4984f
20 Nfa92b02891584eb7805bbc3655530c30
21 Nff3fb882d0fd48f29d2a3248cfab3725
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N1a0a5f2bdcb64c92870cefb15e4747b7
25 schema:citation sg:pub.10.1007/978-1-59745-215-1_10
26 sg:pub.10.1007/s10353-006-0229-9
27 schema:datePublished 2008-04-25
28 schema:datePublishedReg 2008-04-25
29 schema:description BACKGROUND: Surgical resection of liver metastases arising from colorectal cancer is considered the only curative treatment option. However, many patients subsequently experience disease recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of recurrence following potentially curative liver resection. Special emphasis was directed to the importance of response. METHODS: 50 patients with resectable liver metastases received neoadjuvant XELOX or FOLFOX4 for six cycles (3 months). Complete resection of liver metastases was intended thereafter. Assessments included response rate, postoperative morbidity and recurrence-free survival. RESULTS: An objective response was observed in 72% of all patients, including two complete responses. Chemotherapy was well tolerated and the majority of adverse events were mild to moderate (grade 1/2). Potentially curative R0 resection was performed in all patients and postoperative complications were observed in only 12%. The median recurrence-free survival was significantly influenced by tumor response with 24.7 months (95% CI: 4.50 to 44.97) in responding patients, 8.2 months (95% CI: 3.09 to 13.31) in patients with stable disease and 3.0 months (95% CI: 0 to 8.91) in patients with progressive disease. CONCLUSION: These data suggest that neoadjuvant Oxaliplatin based chemotherapy provides high response rates without increased risk of perioperative morbidity. Response to chemotherapy can lead to long-term recurrence-free survival. Neoadjuvant chemotherapy may identify best candidates for a potentially curative treatment approach.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree true
33 schema:isPartOf N874df97abd5847aab1a78e6f83a19e23
34 N9bf91abe95b44c8a84114778bb0968cc
35 sg:journal.1024632
36 schema:keywords FOLFOX4
37 R0 resection
38 XELOX
39 adverse events
40 approach
41 assessment
42 cancer
43 cancer liver metastases
44 candidates
45 chemotherapy
46 colorectal cancer
47 colorectal cancer liver metastases
48 complete resection
49 complete response
50 complications
51 curable colorectal cancer liver metastases
52 curative R0 resection
53 curative liver resection
54 curative treatment approach
55 curative treatment option
56 cycle
57 data
58 disease
59 disease recurrence
60 emphasis
61 events
62 good candidate
63 high response rate
64 importance
65 importance of response
66 liver metastases
67 liver resection
68 long-term recurrence-free survival
69 majority
70 median recurrence-free survival
71 metastasis
72 months
73 morbidity
74 neoadjuvant XELOX
75 neoadjuvant chemotherapy
76 neoadjuvant oxaliplatin
77 objective response
78 options
79 oxaliplatin
80 patients
81 perioperative morbidity
82 postoperative complications
83 postoperative morbidity
84 progressive disease
85 rate
86 recurrence
87 recurrence-free survival
88 resectable liver metastases
89 resection
90 response
91 response rate
92 risk
93 risk of recurrence
94 special emphasis
95 stable disease
96 surgical resection
97 survival
98 treatment approaches
99 treatment options
100 tumor response
101 schema:name Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
102 schema:pagination 120-120
103 schema:productId N27aa1d2ab2bd4187892a6ef509f3a76b
104 N48af29d717d54a37b4649c55173c2f91
105 Nea4ffc48e471417d8f1efb755ce8cc17
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037616467
107 https://doi.org/10.1186/1471-2407-8-120
108 schema:sdDatePublished 2022-01-01T18:19
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N8189a1957ec24d1a94622291db7207a3
111 schema:url https://doi.org/10.1186/1471-2407-8-120
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N04f3a314a9fb4f4590a2b12d481a8d79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Male
117 rdf:type schema:DefinedTerm
118 N0da2a3a354ab40949bc0af6293b55a8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Aged, 80 and over
120 rdf:type schema:DefinedTerm
121 N1a0a5f2bdcb64c92870cefb15e4747b7 rdf:first sg:person.01356576431.32
122 rdf:rest Nfeff75bbfd2d4e7186519e3b7498d971
123 N27aa1d2ab2bd4187892a6ef509f3a76b schema:name dimensions_id
124 schema:value pub.1037616467
125 rdf:type schema:PropertyValue
126 N41829b8d5d144b77adcbe6a64f5c0c19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 N48af29d717d54a37b4649c55173c2f91 schema:name pubmed_id
130 schema:value 18439246
131 rdf:type schema:PropertyValue
132 N5a5da3b12fc1418cbdc5a37a4695840e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Colorectal Neoplasms
134 rdf:type schema:DefinedTerm
135 N5b46e9fa5d484390b1508f67a5d7acc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Antineoplastic Combined Chemotherapy Protocols
137 rdf:type schema:DefinedTerm
138 N5d9d2aa9fd1a4f2d9258317c5f973685 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 N5eb7d61eaa584efbb685761e4207c2f5 rdf:first N6e5898a7115643039e88469b45709be0
142 rdf:rest Nd792985a24214d09a9e5d0cb0b361847
143 N6cdcfbaa5c444c4facbadf83326cc8ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Organoplatinum Compounds
145 rdf:type schema:DefinedTerm
146 N6e5898a7115643039e88469b45709be0 schema:affiliation grid-institutes:None
147 schema:familyName Punzengruber
148 schema:givenName Robert
149 rdf:type schema:Person
150 N71ef2433067e4a639af369b35b65e09d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Prospective Studies
152 rdf:type schema:DefinedTerm
153 N8189a1957ec24d1a94622291db7207a3 schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 N874df97abd5847aab1a78e6f83a19e23 schema:volumeNumber 8
156 rdf:type schema:PublicationVolume
157 N8ebd36a95c2149f2aba2f5f3e92e7ae0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Liver Neoplasms
159 rdf:type schema:DefinedTerm
160 N940addeca8c0418bb7a9e4262a1e7be7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 N99754ecd7c3c4d72872acd6f76898ce4 rdf:first sg:person.01156246422.84
164 rdf:rest rdf:nil
165 N99dce638e5f146e68b9c5ff1fec0a334 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Fluorouracil
167 rdf:type schema:DefinedTerm
168 N9bf91abe95b44c8a84114778bb0968cc schema:issueNumber 1
169 rdf:type schema:PublicationIssue
170 N9e2e7b4c40df4f31915d5663cf06d6f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Oxaloacetates
172 rdf:type schema:DefinedTerm
173 Nbd697bf2b8914054ac8b4834bfbd4428 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Neoplasm Recurrence, Local
175 rdf:type schema:DefinedTerm
176 Nc23bc3b819fe4792b287f671ab515ac4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Treatment Outcome
178 rdf:type schema:DefinedTerm
179 Ncf80dd5db7fa455f81ca78c0c907b032 rdf:first sg:person.01307322440.35
180 rdf:rest N99754ecd7c3c4d72872acd6f76898ce4
181 Nd792985a24214d09a9e5d0cb0b361847 rdf:first sg:person.01201545125.42
182 rdf:rest Ncf80dd5db7fa455f81ca78c0c907b032
183 Ne14e209fb07948418aa9d50de0a60544 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Deoxycytidine
185 rdf:type schema:DefinedTerm
186 Ne2cde5a7e0644a50a42094d31f1dfe8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Leucovorin
188 rdf:type schema:DefinedTerm
189 Nea4ffc48e471417d8f1efb755ce8cc17 schema:name doi
190 schema:value 10.1186/1471-2407-8-120
191 rdf:type schema:PropertyValue
192 Nef969d1ef13549f8b98cd7b44d2769aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Aged
194 rdf:type schema:DefinedTerm
195 Nf8a71bc62ff5416880480e73fa66b16a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Neoadjuvant Therapy
197 rdf:type schema:DefinedTerm
198 Nf95f96f93bc2409e93ebfb9df9c4984f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Adult
200 rdf:type schema:DefinedTerm
201 Nfa92b02891584eb7805bbc3655530c30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Oxaliplatin
203 rdf:type schema:DefinedTerm
204 Nfeff75bbfd2d4e7186519e3b7498d971 rdf:first sg:person.0713515512.66
205 rdf:rest N5eb7d61eaa584efbb685761e4207c2f5
206 Nff3fb882d0fd48f29d2a3248cfab3725 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Capecitabine
208 rdf:type schema:DefinedTerm
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
213 schema:name Oncology and Carcinogenesis
214 rdf:type schema:DefinedTerm
215 sg:journal.1024632 schema:issn 1471-2407
216 schema:name BMC Cancer
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01156246422.84 schema:affiliation grid-institutes:grid.22937.3d
220 schema:familyName Gruenberger
221 schema:givenName Thomas
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156246422.84
223 rdf:type schema:Person
224 sg:person.01201545125.42 schema:affiliation grid-institutes:grid.22937.3d
225 schema:familyName Zielinski
226 schema:givenName Christoph
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201545125.42
228 rdf:type schema:Person
229 sg:person.01307322440.35 schema:affiliation grid-institutes:grid.22937.3d
230 schema:familyName Tamandl
231 schema:givenName Dietmar
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307322440.35
233 rdf:type schema:Person
234 sg:person.01356576431.32 schema:affiliation grid-institutes:grid.22937.3d
235 schema:familyName Gruenberger
236 schema:givenName Birgit
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356576431.32
238 rdf:type schema:Person
239 sg:person.0713515512.66 schema:affiliation grid-institutes:grid.22937.3d
240 schema:familyName Scheithauer
241 schema:givenName Werner
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713515512.66
243 rdf:type schema:Person
244 sg:pub.10.1007/978-1-59745-215-1_10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021439147
245 https://doi.org/10.1007/978-1-59745-215-1_10
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s10353-006-0229-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029392862
248 https://doi.org/10.1007/s10353-006-0229-9
249 rdf:type schema:CreativeWork
250 grid-institutes:None schema:alternateName Department of Internal Medicine, LKH Amstetten, Austria
251 schema:name Department of Internal Medicine, LKH Amstetten, Austria
252 rdf:type schema:Organization
253 grid-institutes:grid.22937.3d schema:alternateName Department of Medicine, Medical University Vienna, Vienna, Austria
254 Department of Surgery, Medical University Vienna, Vienna, Austria
255 schema:name Department of Medicine, Medical University Vienna, Vienna, Austria
256 Department of Surgery, Medical University Vienna, Vienna, Austria
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...